Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mar

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Dietary Influence on Leukemia and Lymphoma Progression

Is Advanced Stage Follicular Lymphoma Curable?

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer

AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia

Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer